Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 165 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1145
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 670
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx, Mansoor Husain, Michael Lehrke, et al.
Circulation (2022) Vol. 146, Iss. 24, pp. 1882-1894
Open Access | Times Cited: 214
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S191-S202
Open Access | Times Cited: 202
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 11, pp. 774-785
Open Access | Times Cited: 159
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 127
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S219-S230
Open Access | Times Cited: 113
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 111
Diabetic Kidney Disease
Sonali Gupta, Mary Dominguez, Ladan Golestaneh
Medical Clinics of North America (2023) Vol. 107, Iss. 4, pp. 689-705
Closed Access | Times Cited: 108
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 104
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies, et al.
Diabetes Care (2023) Vol. 46, Iss. 4, pp. 801-810
Open Access | Times Cited: 52
Combination therapy for kidney disease in people with diabetes mellitus
Daniël H. van Raalte, Petter Bjornstad, David Z.I. Cherney, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 31
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Na Wang, Chun Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3086-3086
Open Access | Times Cited: 23
GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
Heng‐Chih Pan, Jui‐Yi Chen, Hsing‐Yu Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 19
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Sankar D. Navaneethan, Nisha Bansal, Kerri L. Cavanaugh, et al.
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 17
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Ellen M. Apperloo, José Luis Górriz, María José Soler, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 16
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 7
Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations
Muhammad Usman Shah, Alun Roebuck, Bala Srinivasan, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access | Times Cited: 2
Obesity and Endothelial Function
Masato Kajikawa, Yukihito Higashi
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1745-1745
Open Access | Times Cited: 44
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
G.B. John Mancini, Eileen O’Meara, Shelley Zieroth, et al.
Canadian Journal of Cardiology (2022) Vol. 38, Iss. 8, pp. 1153-1167
Open Access | Times Cited: 42
Prognostic nutritional index as a risk factor for diabetic kidney disease and mortality in patients with type 2 diabetes mellitus
Junlin Zhang, Yao Chen, Liang Zou, et al.
Acta Diabetologica (2022) Vol. 60, Iss. 2, pp. 235-245
Open Access | Times Cited: 38
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
Ariana M. Chao, Jena Shaw Tronieri, Anastassia Amaro, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 4449-4461
Open Access | Times Cited: 38
Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials
Qing Yang, Yanlin Lang, Wenjie Yang, et al.
Diabetes Research and Clinical Practice (2023) Vol. 198, pp. 110592-110592
Closed Access | Times Cited: 34
The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
Merlin C. Thomas, Melinda T. Coughlan, Mark E. Cooper
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 253-273
Open Access | Times Cited: 33
Dose–response relationship between dietary antioxidant intake and diabetic kidney disease in the US adults with diabetes
Junlin Zhang, Yao Chen, Liang Zou, et al.
Acta Diabetologica (2023) Vol. 60, Iss. 10, pp. 1365-1375
Closed Access | Times Cited: 29
Page 1 - Next Page

Scroll to top